AgNovos Healthcare attends virtual WCO-ESCEO Congress 2020 from August 20th – 22nd

AgNovos Healthcare will participate in the virtual WCO IOF-ESCEO Congress ( and exhibit the CE-marked OSSURE® LOEP® Kit. This year we will present a poster titled “GLOBAL CLINICAL EXPERIENCE EVALUATES A SAFETY AND EFFICACY OF THE AGN1 LOCAL OSTEO-ENHANCEMENT PROCEDURE TO REPLACE BONE LOST IN THE PROXIMAL FEMUR OF OSTEOPOROTIC WOMEN” (P1204 , J. De Schepper, C. Fang, B. Huber) and invite you to visit our virtual booth, to view the ESCEO-AGNOVOS young investigator awards and to join the Meet-The-Expert Live-Session hosted by Prof. Andreas Kurth.

Read more

AgNovos Healthcare and conference attendance this year

AgNovos had planned to attend the following conferences in 2020, all of which have been impacted by the coronavirus:

The worldwide spread of coronavirus pandemic has understandably disrupted plans for numerous congresses. For congresses that will be hosted virtually or rescheduled, we look forward to participating and will announce updates here. Please check regularly for the latest news.

For those conferences that will be cancelled completely, we plan to use other means to share the scientific updates that we had planned for the congress(es).

We look forward to seeing you at congresses as soon as it is feasible.


Read more

Paper showing that LOEP immediately increases proximal femur strength is in top 10% of 2018-2019 downloads in the Journal of Orthopedic Research (JOR)

The manuscript describes a study evaluating the immediate impact of AGN1 LOEP treatment on the strength of osteoporotic femurs. The manuscript titled “In vitro injection of osteoporotic cadaveric femurs with a triphasic calcium‐based implant confers immediate biomechanical integrity” was published on February 21, 2019 and can be read here.

The paper was among the top 10% of downloads of all papers published between January 2018 and December 2019 in the Journal of Orthopedic Research (JOR).

Read more

AgNovos Healthcare has generated strong interest with the Breakthrough Designation by the FDA and was mentioned in reputable press portals

The recently issued press release on the FDA's "Breakthrough Designation" for AgNovos' newest investigational product, AGN1 Local Osteo-enhancement Procedure (LOEP) Small Volume (SV) Kit, has generated a strong of interest in the industry and has been posted on several reputable press portals as for example and




Read more